Provider Reviews

Trimi vs Try Ageless: Compounded GLP-1 Plans Compared

Trimi vs Try Ageless pits two telehealth programs that sell compounded semaglutide and tirzepatide. Quick verdict: Trimi is centered on low flat per-dose pricing and overnight shipping, while Try Ageless emphasizes multiple formats including needle-free oral drops and a built-in discount structure.

See Trimi plans and pricing

Headline differences: pricing, formats, and guarantees

Both programs prescribe compounded GLP-1 medications via licensed U.S. clinicians and ship to your door, but they differ in three main ways: price structure, medication formats, and consumer protections. Trimi advertises compounded semaglutide from $99/mo on the annual plan and tirzepatide at $125/month with flat pricing that does not rise as dose increases and free overnight, temperature controlled shipping. Try Ageless lists semaglutide from $199/mo, tirzepatide from $249/mo, and needle-free tirzepatide oral drops from $159/mo on yearly plans and states a discount is already applied to every plan plus a stackable SLIM50 code for an extra $50 off.

Medication formats and flexibility

Format is a major decision point in Trimi vs Try Ageless. Trimi offers compounded semaglutide and tirzepatide as injectable compounded medications. Try Ageless sells compounded semaglutide injection, compounded tirzepatide injection, and needle-free tirzepatide oral drops. Try Ageless highlights that the drops are a daily sublingual liquid and that patients can switch molecules or formats under the same plan with no new consult fee.

View Try Ageless formats and drops

Pricing structure and entry cost

Compare advertised entry points and pricing mechanics. Trimi promotes compounded semaglutide from $99/mo on annual plans and tirzepatide from $125/mo with flat pricing at every dose and a 6 month money back promise if you follow the plan and do not lose weight, subject to terms. Try Ageless emphasizes that a discount is already applied to every plan, listing the lowest yearly per-month price as $159/mo for drops, $199/mo for semaglutide, and $249/mo for tirzepatide, and that code SLIM50 stacks for an extra $50 off. Try Ageless also notes lowest advertised prices require the prepaid yearly plan and that monthly rates are higher on month-to-month billing.

Clinical oversight, pharmacies, and regulatory notes

Both vendors use licensed U.S. clinicians to prescribe compounded medications. Trimi states its clinical oversight is provided by Arora Health with Medical Director Dr. Sean Arora, MD, and that compounding is performed by state-licensed 503A pharmacies including VialsRx and GreenwichRx, with certificates of analysis available on request. Try Ageless says it is operated by Lovely Meds, Inc and dispenses compounded medications prepared by state-licensed U.S. 503A pharmacies and is LegitScript-certified and HIPAA-compliant. Both sources include the regulatory qualification that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Try Ageless specifically notes that oral tirzepatide drops are an off-label compounded format and that tirzepatide is not FDA-approved in oral form.

Criteria Trimi Try Ageless
Starting monthly price Semaglutide from $99/mo; tirzepatide $125/mo Semaglutide from $199/mo; tirzepatide from $249/mo; drops from $159/mo
Formats offered Compounded semaglutide and tirzepatide injections Semaglutide injection, tirzepatide injection, tirzepatide oral drops
Shipping Free overnight, temperature controlled shipping Free discreet shipping
Price structure Flat pricing that never rises as dose increases; annual plans noted Discount already applied to plans; lowest prices on prepaid yearly plans; SLIM50 code stacks
Clinical oversight Arora Health network; named medical director Dr. Sean Arora, MD Operated by Lovely Meds, Inc; licensed U.S. clinicians; LegitScript-certified
Guarantee or refund 6 month money back promise, terms apply No money back promise stated in captured evidence
Regulatory note Compounded medications are not FDA-approved Compounded medications are not FDA-approved; oral tirzepatide is off-label

Start with Trimi if flat pricing matters

Who should prioritize each distinction

When choosing between Trimi vs Try Ageless, consider these supported tradeoffs. If your priority is the lowest per-month advertised semaglutide price and free overnight shipping with a stated 6 month money back promise when you follow the plan, the evidence supports Trimi. If your priority is format choice, especially access to needle-free tirzepatide oral drops, built-in plan discounts and the ability to switch formats under one plan, the evidence supports Try Ageless.

Compare Try Ageless plans now

Final thoughts on Trimi vs Try Ageless

Trimi vs Try Ageless narrows to whether you value lower flat per-dose pricing and overnight shipping plus a 6 month money back promise at Trimi, or whether you value format flexibility, an already applied discount and a needle-free tirzepatide drops option at Try Ageless. Both use compounded medications prescribed by licensed clinicians and both note compounded products are not FDA-approved.

Choose Trimi plans

Choose Trimi if you want compounded semaglutide from $99/mo, flat pricing that never rises as your dose increases, free overnight shipping, named compounding pharmacies, and a 6 month money back promise when terms are met. Choose Try Ageless if you want multiple GLP-1 formats including needle-free tirzepatide drops from $159/mo, a discount built into every plan plus a stackable SLIM50 code, B12 included in plans, and the ability to switch formats under one plan with no new consult fee.

Ready to Compare Telehealth Providers?

Explore leading providers β€” physician-supervised, all-inclusive pricing, and free home delivery.

Compare All Providers β†’

Related articles

Medical disclaimer: This page is for informational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any treatment. We may earn a commission from partner links on this page - see our advertising disclosure.